303 related articles for article (PubMed ID: 11391574)
1. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Ravandi F; Kantarjian HM; Talpaz M; O'Brien S; Faderl S; Giles FJ; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios MB; Albitar M
Cancer; 2001 Jun; 91(11):1964-72. PubMed ID: 11391574
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Giles FJ; Kantarjian HM; Cortes J; Thomas DA; Talpaz M; Manshouri T; Albitar M
Cancer; 1999 Sep; 86(5):805-13. PubMed ID: 10463979
[TBL] [Abstract][Full Text] [Related]
3. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
Selleri C; Maciejewski JP; Pane F; Luciano L; Raiola AM; Mostarda I; Salvatore F; Rotoli B
Blood; 1998 Aug; 92(3):981-9. PubMed ID: 9680367
[TBL] [Abstract][Full Text] [Related]
4. ECP-treated lymphocytes of chronic graft-versus-host disease patients undergo apoptosis which involves both the Fas/FasL system and the Bcl-2 protein family.
Di Renzo M; Rubegni P; Sbano P; Cuccia A; Castagnini C; Pompella G; Pasqui AL; Capecchi PL; Auteri A; Laghi Pasini F; Fimiani M
Arch Dermatol Res; 2003 Sep; 295(5):175-82. PubMed ID: 12883827
[TBL] [Abstract][Full Text] [Related]
5. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles FJ; Pierce S; Albitar M
Cancer; 2000 Feb; 88(3):570-6. PubMed ID: 10649249
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
7. Significance of FHIT expression in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M
Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.
Lickliter JD; Kratzke RA; Nguyen PL; Niehans GA; Miller JS
Exp Hematol; 1999 Oct; 27(10):1519-27. PubMed ID: 10517493
[TBL] [Abstract][Full Text] [Related]
9. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.
Raqib R; Ekberg C; Sharkar P; Bardhan PK; Zychlinsky A; Sansonetti PJ; Andersson J
Infect Immun; 2002 Jun; 70(6):3199-207. PubMed ID: 12011015
[TBL] [Abstract][Full Text] [Related]
11. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.
Selleri C; Sato T; Del Vecchio L; Luciano L; Barrett AJ; Rotoli B; Young NS; Maciejewski JP
Blood; 1997 Feb; 89(3):957-64. PubMed ID: 9028327
[TBL] [Abstract][Full Text] [Related]
12. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
13. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
Tang LJ; Chen HC; Peng XH
Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
15. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Verstovsek S; Kantarjian H; Manshouri T; O'Brien S; Faderl S; Talpaz M; Cortes J; Albitar M
Cancer; 2002 Mar; 94(5):1517-21. PubMed ID: 11920509
[TBL] [Abstract][Full Text] [Related]
17. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
18. The role of FAS-mediated apoptosis in chronic myelogenous leukemia.
Selleri C; Maciejewski JP
Leuk Lymphoma; 2000 Apr; 37(3-4):283-97. PubMed ID: 10752980
[TBL] [Abstract][Full Text] [Related]
19. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
20. Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease.
Starcevic SL; Elferink C; Novak RF
J Natl Cancer Inst; 2001 May; 93(10):776-82. PubMed ID: 11353788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
